Whilst the development and licensing of the Bexsero Men B vaccine is an important advance, there are still questions to be resolved as to how good it will be. For example, it is only predicted to be effective against 73 - 88% of UK strains of Men B bacteria. It is therefore important and widely acknowledged that the scientific and medical community continue Men B vaccine research. We all strive for a universal vaccine that will eradicate Men B disease and this project will contribute to that urgently needed goal.
The researchers plan to use a novel approach to find further vaccine candidates that will either help to improve, or be an alternative to the currently available MenB vaccine Bexsero.
Blood will be taken from patients who have had Men B disease and single cells that produce antibodies will be identified and isolated. The genes that make antibodies are cloned so that large amounts of individual antibodies can be produced in the laboratory. Each individual antibody will be tested for its ability to bind and kill Men B cells that are known to cause disease in the UK. The protein molecules on the surface of Men B which are recognised by “killing” antibodies will be found. Such Men B proteins are highly promising vaccine candidates.
The difference it will make
This method has not been used on Men B before and so is likely to find completely novel vaccine candidates that could be used to improve protection against Men B disease.
Summary of results and potential impact of the project
A blood sample taken from a patient who was recovering from Men B disease was used to produce 139 different antibodies. Eight of these antibodies recognised, and bound to, Men B strains, including those that are known to cause disease in the UK and those that are not covered by Bexsero®. Of these eight antibodies, three were able to kill Men B stains and interestingly, none of these killer antibodies recognised any of the proteins in the Bexsero® vaccine. This means that there are other Men B proteins that could be new vaccine candidates.
The researchers have been able to narrow down the identity of these proteins to a small number of possibilities and the manufacturer of the Bexsero® vaccine has now expressed interest in taking this work further. The next stage of this work will be to determine whether these new proteins can actually be used in a vaccine.
This research has shown that this approach can be used to identify potential new vaccine antigens, not only for meningococcal disease, but also for other infections such as pneumococcal disease.
Help support this research
This research is only made possible by the generous support of people like YOU. Help us continue by donating, or raising funds for our work. On behalf of everyone who will benefit, now and in the future, thank you.
Prof Paul Langford, Prof Simon Kroll, Dr Simon Nadel, Prof Gavin Screaton and Dr Fadil Bidmos
Imperial College London, St Mary’s Campus
If you would like more information about this project, or our research in general, please contact us on email@example.com.